Alzheimer's Drug Approval
A delay in the approval of Donanumab raises questions about the FDA's review process and its implications for Alzheimer's treatments. The discussion highlights the differences in trial designs between Donanumab and Aduhelm, emphasizing the need for careful evaluation of safety data and efficacy measures. Insights into the FDA's cautious approach reflect on the lessons learned from past controversies surrounding Alzheimer's medications.In this clip
From this podcast
Science Friday
The Bumpy Road To Approving New Alzheimer’s Drugs
Related Questions